Universal COVID-19 Vaccine Targeting SARS-CoV-2 Envelope Protein
Open Access
- 1 January 2021
- journal article
- research article
- Published by Scientific Research Publishing, Inc. in World Journal of Vaccines
- Vol. 11 (03), 19-27
- https://doi.org/10.4236/wjv.2021.113003
Abstract
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), had caused over 382 million cases and over 2.7 million deaths globally as of 23 March 2021. By that date, at least 10 SARS-CoV-2 variants had emerged. The transmissibility and lethality of the variants are higher than those of the Wuhan reference strain. Therefore, a universal vaccine for the reference strain and all variants (present and future) is indispensable. The coronavirus envelope (E) protein is an integral membrane protein crucial to the viral lifecycle and the pathogenesis of coronaviruses. The SARS-CoV-2 E protein has a postsynaptic density protein 95/Drosophila disc large tumor suppressor/zonula occludens-1 (PDZ) binding motif (PBM), and its interaction with PDZ-domain-2 of the human tight junction protein may interrupt the integrity of lung epithelium. Furthermore, the SARS-CoV-2 E protein itself is a homopentameric cation channel viroporin, which may be involved in viral release. This protein is thus a potential target for the development of a universal COVID-19 vaccine, because of its highly conserved amino acid sequence. The variant mutations occur mainly in the spike protein, and conservation of E protein remained in most Variants of Concern (VOC). Only one of the extant VOC have mutations in the E protein that P71L mutation occurs in the South African variant 501Y.V2 (B.1.351). If a vaccine is designed to target E protein, two scenarios are possible: 1) SARS-CoV-2 maintains a highly conserved E protein amino acid sequence, rendering the virus consistently or permanently susceptible to the vaccine; or 2) the E protein mutates and new variants evolve accordingly. In scenario 2, the tertiary structure and function of the E protein homopentameric cation channel viroporin, PBM, or other aspects affecting pathogenicity would be attenuated. Either scenario would thus ameliorate the pandemic. I therefore propose that a vaccine targeting the SARS-CoV-2 E protein would be effective against the Wuhan reference strain and all current and future SARS-CoV-2 variants. Efforts to create E protein-based vaccines are ongoing. Further research and clinical trials are needed to realize this universal COVID-19 vaccine.Keywords
This publication has 25 references indexed in Scilit:
- An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) proteinPublished by Research Square Platform LLC ,2020
- Design of a Multiepitope-Based Peptide Vaccine against the E Protein of Human COVID-19: An Immunoinformatics ApproachBioMed Research International, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting WuhanEmerging Microbes & Infections, 2020
- The Infectious Bronchitis Coronavirus Envelope Protein Alters Golgi pH To Protect the Spike Protein and Promote the Release of Infectious VirusJournal of Virology, 2019
- Coronavirus envelope protein: current knowledgeVirology Journal, 2019
- Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese batsEmerging Microbes & Infections, 2018
- The SARS Coronavirus E Protein Interacts with PALS1 and Alters Tight Junction Formation and Epithelial MorphogenesisMolecular Biology of the Cell, 2010
- A Severe Acute Respiratory Syndrome Coronavirus That Lacks the E Gene Is Attenuated In Vitro and In VivoJournal of Virology, 2007